Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Prospective, Randomized Controlled Trial Assessing the Clinical Impact of Integrated Pharmacogenetic Testing on Selected OASIS Metrics, Re-hospitalizations and Emergency Department Visits

NCT02378220 is registered in ClinicalTrials.gov with Genelex Corporation as lead sponsor.

NCT NCT02378220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02378220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Prospective, Randomized Controlled Trial Assessing the Clinical Impact of Integrated Pharmacogenetic Testing on Selected OASIS Metrics, Re-hospitalizations and Emergency Department Visits
Lead sponsor
Genelex Corporation
Phase
Not applicable
Overall status
Completed
Start date
March 31, 2015
Completion date
March 31, 2016
Enrollment
110 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adverse drug events, adverse drug reactions, cytochrome p450 cyp2c19 enzyme deficiency, cytochrome p450 cyp2c9 enzyme deficiency, cytochrome p450 cyp2d6 enzyme deficiency, cytochrome p450 cyp3a enzyme deficiency, cytochrome p450 enzyme deficiency, drug interaction potentiation, drug metabolism, poor, cyp2c19-related, drug metabolism, poor, cyp2d6-related, poor metabolizer due to cytochrome p450 cyp2c19 variant, poor metabolizer due to cytochrome p450 cyp2c9 variant, poor metabolizer due to cytochrome p450 cyp2d6 variant